A broad-spectrum triazole antifungal agent
Related Products
Labeled Version(s)
30079Isavuconazole-d4
Pro-drug Form(s)
23950Isavuconazonium (sulfate)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Isavuconazole

Item No. 26211

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[2-[(1R,2R)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-benzonitrile
CAS Number
241479-67-4
Synonyms
  • BAL4815
  • RO 0094815
Molecular Formula
C22H17F2N5OS
Formula Weight
437.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMF:PBS (pH 7.2) (1:4): 0.25 mg/mlDMSO: 20 mg/mlEthanol: 5 mg/ml
λmax
285 nm
SMILES
FC(C=CC(F)=C1)=C1[C@](CN2N=CN=C2)(O)[C@@H](C)C3=NC(C4=CC=C(C#N)C=C4)=CS3
InChi Code
InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
InChi Key
DDFOUSQFMYRUQK-RCDICMHDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $123

    Add

    10 mg

    $195

    Add

    50 mg

    $722

    Add

    100 mg

    $842

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Isavuconazole is a broad-spectrum triazole antifungal agent.1 It inhibits the growth of clinical isolates of A. fumigatus, A. terreus, A. flavus, and A. lentulus (MIC90s = 0.39, 0.39, 2, and 0.25 mg/L, respectively) as well as C. albicans, C. krusei, and C. parapsilosis (MIC50s = 0.03, 0.06, and 0.03 mg/L, respectively).1,2,3,4 Isavuconazole also inhibits the growth of several other fungal species, including clinical isolates of C. neoformans and C. gattii (MIC90s = 0.032 and 0.125 mg/L, respectively).1,3 Formulations containing isavuconazole have been used in the treatment of invasive aspergillosis and mucormycosis.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Yamazaki, T., Inagaki, Y., Fujii, T., et al. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents 36(4), 324-331 (2010).

    2. Rudramurthy, S.M., Chakrabarti, A., Geertsen, E., et al. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn. Microbiol. Infect. Dis. 71(4), 370-377 (2011).

    3. Datta, K., Rhee, P., Byrnes, E., III, et al. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J. Clin. Microbiol. 51(9), 3090-3093 (2013).

    4. Astvad, K.M.T., Hare, R.K., and Arendrup, M.C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin. Microbiol. Infect. 23(11), 882-887 (2017).